Board Meeting Details

The Board of Directors meeting was held on August 14, 2026, commencing at 01:00 PM and concluding at 04:20 PM. The board considered and approved:

  • Unaudited Standalone and Consolidated Financial Results for quarter ended June 30, 2026
  • Notice of Annual General Meeting and Board's report with annexures
  • Annual General Meeting scheduled for Wednesday, September 30, 2026 at 02:00 PM through Video Conferencing/Other Audio Visual Means
  • Cut-off date for AGM: September 23, 2026
  • Register of members and share transfer books closure: September 24, 2026 to September 30, 2026 (both days inclusive)
  • E-voting period: September 27, 2026 (9:00 AM) to September 29, 2026 (5:00 PM)
  • Appointment of Mr. Yash Mehta, Practicing Company Secretary as Scrutinizer for e-voting

Standalone Financial Results (Q1 FY27 - Quarter ended June 30, 2026)

Financial Performance (₹ in Lakhs):

  • Revenue from Operations: ₹1,433.29
  • Other Income: ₹50.73
  • Total Revenue: ₹1,524.02
  • Total Expenses: ₹1,442.73
  • Profit before tax: ₹81.29
  • Tax Expense: ₹20.53 (Current Tax: ₹21.97, Deferred Tax: ₹1.44)
  • Net Profit for the period: ₹60.76
  • Total Comprehensive Income: ₹60.76
  • Earnings Per Share (Basic & Diluted): ₹0.61

Capital Structure:

  • Paid-up Equity Share Capital: ₹1,000.00 (Face Value ₹10 each)

Consolidated Financial Results (Q1 FY27 - Quarter ended June 30, 2026)

Financial Performance (₹ in Lakhs):

  • Revenue from Operations: ₹2,071.15
  • Other Income: ₹13.35
  • Total Revenue: ₹2,084.49
  • Total Expenses: ₹2,452.42
  • Loss before tax: ₹(367.93)
  • Tax Expense: ₹38.61 (Current Tax: ₹43.49, Deferred Tax: ₹(4.88))
  • Net Loss for the period: ₹(406.54)
  • Share of Profit/(Loss) of Associates and Joint Ventures: ₹2.30
  • Profit After Tax and Share of Profit: ₹(404.23)
  • Total Comprehensive Income: ₹(404.23)
  • Net profit attributable to Owners: ₹(144.73)
  • Net profit attributable to Non-controlling interest: ₹(259.50)
  • Earnings Per Share (Basic & Diluted): ₹(1.45)

Subsidiaries and Joint Ventures Included:

1. Evagrace Pharma Private Limited

2. Ritz Formulations Private Limited

3. Sungrace Pharma Private Limited

4. Azillian Healthcare Private Limited

5. Calborn Lifescience Private Limited

6. Medico Lab (Joint venture)

Auditor's Review

M/s. V Goswami & Co, Statutory Auditors issued unmodified review reports for both standalone and consolidated results. For consolidated results, the auditors noted they did not review the interim financial results of subsidiaries, which reflected total revenues of ₹1,344.23 Lakhs and total net loss after tax of ₹(464.99) Lakhs for the quarter.

Additional Information

  • The company operates in a single segment during the quarter
  • Figures for quarter ended March 31, 2026 are balancing figures between audited annual figures and reviewed YTD figures
  • Previous period figures have been re-grouped/reclassified for comparability

Key Standalone Financial Information Comparison

Quarter ended June 30, 2026 (Unaudited) vs Previous Periods:

  • Revenue from Operations: ₹1,524.02 (vs ₹1,655.31 in Q4 FY26; ₹1,370.86 in Q1 FY26)
  • Profit before tax: ₹81.29 (vs ₹73.08 in Q4 FY26; ₹73.68 in Q1 FY26)
  • Net profit after tax: ₹60.76 (vs ₹42.41 in Q4 FY26; ₹55.60 in Q1 FY26)